hVIVO has announced that it has received notification of a ‘significant’ HCT contract cancellation alongside a postponement and a smaller study cancellation. While the wider CRO landscape has met with headwinds in recent months, our assumption is that the most recent moves from the Trump administration to initiate and implement policies to tackle drug pricing in the US has resulted in drug developers further deferring decisions, or cancelling certain existing programmes, resulting in material vo ....
